Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T87374
|
||||
Target Name |
COVID-19 spike glycoprotein (S)
|
||||
Synonyms |
COVID-19 S glycoprotein; COVID-19 E2; COVID-19 Peplomer protein
|
||||
Gene Name |
COVID-19 S
|
||||
Target Status |
Target in Phase 2 Trial
|
[1] | |||
Disease | [+] 1 Target-related Diseases | + | |||
1 | COVID-19 [ICD-11: 1D6Y] | ||||
Function |
Mediates fusion of the virion and cellular membranes by acting as a class I viral fusion protein. Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and target cell membrane fusion, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes.
|
||||
BioChemical Class |
Betacoronaviruses spike protein family
|
||||
UniProt ID | |||||
Drugs and Modes of Action | |||||
Drugs in Phase 2 Trial | [+] 1 Drugs in Phase 2 Trial | + | |||
1 | Nafamostat | Drug Info | Phase 2 Trial | COVID-19 | [2] |
Investigative agents | [+] 1 Investigative agents | + | |||
1 | Toremifene | Drug Info | Investigative | COVID-19 | [3] |
Mode of Action | [+] 1 Modes of Action | + | |||
Inhibitor | [+] 2 Inhibitor drugs | + | |||
1 | Nafamostat | Drug Info | [1] | ||
2 | Toremifene | Drug Info | [3] |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.